Frontiers in Virology (Mar 2024)
Virological characteristics correlating with SARS-CoV-2 spike protein fusogenicity
- MST Monira Begum,
- Kimiko Ichihara,
- Otowa Takahashi,
- Hesham Nasser,
- Hesham Nasser,
- Michael Jonathan,
- Michael Jonathan,
- Kenzo Tokunaga,
- Isao Yoshida,
- Mami Nagashima,
- Kenji Sadamasu,
- Kazuhisa Yoshimura,
- The Genotype to Phenotype Japan (G2P-Japan) Consortium,
- Kei Sato,
- Kei Sato,
- Kei Sato,
- Kei Sato,
- Kei Sato,
- Kei Sato,
- Kei Sato,
- Terumasa Ikeda,
- Keita Matsuno,
- Naganori Nao,
- Hirofumi Sawa,
- Shinya Tanaka,
- Masumi Tsuda,
- Lei Wang,
- Yoshikata Oda,
- Zannatul Ferdous,
- Kenji Shishido,
- Takasuke Fukuhara,
- Tomokazu Tamura,
- Rigel Suzuki,
- Saori Suzuki,
- Hayato Ito,
- Jumpei Ito,
- Yu Kaku,
- Naoko Misawa,
- Arnon Plianchaisuk,
- Ziyi Guo,
- Alfredo Jr. Hinay,
- Keiya Uriu,
- Yusuke Kosugi,
- Shigeru Fujita,
- Jarel Elgin Mendoza Tolentino,
- Luo Chen,
- Lin Pan6,
- Mai Suganami,
- Mika Chiba,
- Ryo Yoshimura,
- Kyoko Yasuda,
- Keiko Iida,
- Naomi Ohsumi,
- Adam Patrick Strange,
- Hiroyuki Asakura,
- Isao Yoshida,
- So Nakagawa,
- Akifumi Takaori-Kondo,
- Kotaro Shirakawa,
- Kayoko Nagata,
- Ryosuke Nomura,
- Yoshihito Horisawa,
- Yusuke Tashiro,
- Yugo Kawai,
- Kazuo Takayama,
- Rina Hashimoto,
- Sayaka Deguchi,
- Yukio Watanabe,
- Ayaka Sakamoto,
- Naoko Yasuhara,
- Takao Hashiguchi,
- Tateki Suzuki,
- Kanako Kimura,
- Jiei Sasaki,
- Yukari Nakajima,
- Hisano Yajima,
- Takashi Irie,
- Ryoko Kawabata,
- Kaori Tabata,
- Ryo Shimizu1,
- Yuka Mugita1,
- Takamasa Ueno,
- Chihiro Motozono,
- Mako Toyoda,
- Akatsuki Saito,
- Maya Shofa,
- Yuki Shibatani,
- Tomoko Nishiuchi
Affiliations
- MST Monira Begum
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- Kimiko Ichihara
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- Otowa Takahashi
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- Hesham Nasser
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- Hesham Nasser
- Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
- Michael Jonathan
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- Michael Jonathan
- Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
- Kenzo Tokunaga
- Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan
- Isao Yoshida
- Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- Mami Nagashima
- Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- Kenji Sadamasu
- Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- Kazuhisa Yoshimura
- Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- The Genotype to Phenotype Japan (G2P-Japan) Consortium
- Kei Sato
- Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Kei Sato
- International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Kei Sato
- International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Kei Sato
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Kei Sato
- 0Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
- Kei Sato
- 1Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan
- Kei Sato
- 2CREST, Japan Science and Technology Agency, Kawaguchi, Japan
- Terumasa Ikeda
- Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- Keita Matsuno
- Naganori Nao
- Hirofumi Sawa
- Shinya Tanaka
- Masumi Tsuda
- Lei Wang
- Yoshikata Oda
- Zannatul Ferdous
- Kenji Shishido
- Takasuke Fukuhara
- Tomokazu Tamura
- Rigel Suzuki
- Saori Suzuki
- Hayato Ito
- Jumpei Ito
- Yu Kaku
- Naoko Misawa
- Arnon Plianchaisuk
- Ziyi Guo
- Alfredo Jr. Hinay
- Keiya Uriu
- Yusuke Kosugi
- Shigeru Fujita
- Jarel Elgin Mendoza Tolentino
- Luo Chen
- Lin Pan6
- Mai Suganami
- Mika Chiba
- Ryo Yoshimura
- Kyoko Yasuda
- Keiko Iida
- Naomi Ohsumi
- Adam Patrick Strange
- Hiroyuki Asakura
- Isao Yoshida
- So Nakagawa
- Akifumi Takaori-Kondo
- Kotaro Shirakawa
- Kayoko Nagata
- Ryosuke Nomura
- Yoshihito Horisawa
- Yusuke Tashiro
- Yugo Kawai
- Kazuo Takayama
- Rina Hashimoto
- Sayaka Deguchi
- Yukio Watanabe
- Ayaka Sakamoto
- Naoko Yasuhara
- Takao Hashiguchi
- Tateki Suzuki
- Kanako Kimura
- Jiei Sasaki
- Yukari Nakajima
- Hisano Yajima
- Takashi Irie
- Ryoko Kawabata
- Kaori Tabata
- Ryo Shimizu1
- Yuka Mugita1
- Takamasa Ueno
- Chihiro Motozono
- Mako Toyoda
- Akatsuki Saito
- Maya Shofa
- Yuki Shibatani
- Tomoko Nishiuchi
- DOI
- https://doi.org/10.3389/fviro.2024.1353661
- Journal volume & issue
-
Vol. 4
Abstract
IntroductionThe severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike (S) protein is essential in mediating membrane fusion of the virus with the target cells. Several reports demonstrated that SARS-CoV-2 S protein fusogenicity is reportedly closely associated with the intrinsic pathogenicity of the virus determined using hamster models. However, the association between S protein fusogenicity and other virological parameters remains elusive.MethodsIn this study, we investigated the virological parameters (e.g., S1/S2 cleavage efficiency, plaque size, pseudoviral infectivity, pseudovirus entry efficiency, and viral replication kinetics) of eleven previous variants of concern (VOCs) and variants of interest (VOIs) correlating with S protein fusogenicity.Results and discussionS protein fusogenicity was found to be strongly correlated with S1/S2 cleavage efficiency and plaque size formed by clinical isolates. However, S protein fusogenicity was less associated with pseudoviral infectivity, pseudovirus entry efficiency, and viral replication kinetics. Taken together, our results suggest that S1/S2 cleavage efficiency and plaque size could be potential indicators to predict the intrinsic pathogenicity and S protein fusogenicity of newly emerged SARS-CoV-2 variants.
Keywords
